Rituximab versus cyclophosphamide for ANCA-associated vasculitis. - Wikidata - wikimedia - TriplyDB

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q35109118

about

Progress in treatment of ANCA-associated vasculitis Interventions for renal vasculitis in adults The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China Recent advances in understanding and treating vasculitis Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations Therapeutic advances in the treatment of vasculitis Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives New developments in the genetics, pathogenesis, and therapy of IgA nephropathy Cellular targeting in autoimmunity Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging Understanding the role of B cells in atherosclerosis: potential clinical implications B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production Lupus nephritis: the evolving role of novel therapeutics Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Anti-TNF-alpha therapy and systemic vasculitis.Updates in ANCA-associated vasculitis Rituximab in autoimmune diseases The role of biologics in treatment of connective tissue disease-associated interstitial lung disease What is new in the management of rapidly progressive glomerulonephritis?Pathophysiology of ANCA-associated small vessel vasculitis Pathogenesis of ANCA-associated vasculitis The immunopathology of ANCA-associated vasculitis Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis Genetically distinct subsets within ANCA-associated vasculitis Gastrointestinal aspects of vasculitides.B cells and atherosclerosis.Treatment of renal manifestations of ANCA-associated vasculitis.[Remission induction in ANCA-associated vasculitis: Follow-up data of the RAVE study].ImmPort: disseminating data to the public for the future of immunology.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.

P2860

Q21195258-E69788E6-75B6-4598-80CB-8F8CE2DDBEF7 Q24187038-B285387A-7020-45D1-9B7C-46FEBF353B30 Q26740451-B00D4D78-6B79-49B9-BB2A-30B9731E4B45 Q26740453-D370B0E7-9C6A-4D32-A1FF-EDA162F68C28 Q26747046-5DBF32C9-6F00-4DD5-A5AD-1B01BF18FA7C Q26748200-5C7E6041-6D9B-4B5C-AB98-D7C4ECAA39A3 Q26750499-3A1C184B-775E-4134-BF6D-3B86EE64720C Q26751357-8354396E-E184-4FA3-BD31-7F40C528052F Q26765803-8990B4FC-DD94-4ACA-A9B8-C53B9044C743 Q26775756-F8CA15A0-C670-45AE-9284-15D4F42E1CAE Q26776308-0C868080-EBE2-406D-9783-7E56EA8741BC Q26786248-4A54C86F-72BB-48EE-A68E-756749C64C63 Q26824580-EF3D4478-0798-49F5-A5F4-33D5C8CC46FC Q26864297-3AD6B948-973C-4DA1-AEA4-8F09B6B84C72 Q26864381-CD985645-AF65-4D16-9F6F-D52C5F30DA82 Q26991813-123FF816-D9E2-48C8-BA2C-6907BBC07F26 Q26996644-877CB4F1-D7AC-4DC3-BAF0-B68973E621D9 Q26998390-4EC49709-67BE-4081-8815-8931382631B7 Q27008053-A100E2CE-AE4B-48EF-B23F-1519A96320F7 Q27021256-D665E1DE-CB42-4056-A8B9-FB7D895E7AA0 Q27022117-4A56C3FF-ADF4-4633-8931-A1C67A9C7AC7 Q27025692-3E477B15-CD6B-42C0-AD07-9AEEDBACFD11 Q27687590-67BB8ABF-6B54-4D5E-B5B3-25FC6521D1D8 Q28069897-3A0B05B1-350A-4E4A-BC9E-ADE69F3DEDB4 Q28076091-C159533B-7503-4F66-9B5D-59A0B71EC748 Q28082021-9B2BF9CA-CA5B-4F50-B0AE-AF7C7DFF111C Q28259540-308FA8BC-3CBA-44B6-8B55-9CB0E8221124 Q28383761-F4B38590-1499-4DE8-AEBF-F606B67EF2E8 Q28390438-DA541667-165B-49A0-A5C0-9792E173D33F Q28391531-152E8B70-3009-4A3B-80CA-6631BA078C88 Q28393792-5B9FABCF-66D4-4DD0-9B00-D8B78152F804 Q28607461-5991F6FD-70D6-49B9-A5AC-988D6B34DBF7 Q28732725-48874C6F-2BEA-4135-8388-5C1B5B10582D Q28943363-9C0EBB38-42A0-4E15-A51B-E061391D286C Q30240787-B0C5C349-7865-48C5-891E-3548794A8ABE Q30252928-4C92082D-773E-4806-A3CC-08C705ADDE4C Q30486655-52345A82-CEB2-42EC-B93C-3C1284E1D99B Q30704972-81647E94-31EF-4F79-8065-91C1664BBDFC Q30813520-A935086E-065E-492C-AE6B-FFBF2BF99F27 Q30849537-02848533-24B2-4B0C-BF8C-E8AF10677900

P2860

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q35109118

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@ast

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@en

type

label

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@ast

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@en

prefLabel

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@ast

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@en

P1433

Q35109118-3468CE37-E7D4-4BA6-9D35-3F22494A06B5

P1476

Q35109118-3A3D2936-7CA5-4F61-BBAC-6C58EEA374CE

P2093

Q35109118-0FAC54CF-FFCD-4D85-AB55-8650484A6B7A

Q35109118-1C57F8FB-70F0-405B-B43D-894D4C6A0359

Q35109118-32446DF8-0518-41D2-ACAB-CC3AC7345540

Q35109118-32F08C41-7CB5-496E-ADAC-0A9DEB55FF21

Q35109118-395B2FEF-59DA-44DF-ABF7-D166E103A6DA

Q35109118-4DC7C840-C5A7-42DD-B14F-FA5A473709F9

Q35109118-4EDC9B58-83DD-4CC6-98CB-F444C68D28C3

Q35109118-50D70392-D3FD-4159-8CDC-177965A42FA7

Q35109118-5D245D79-FAFA-4132-A209-596B2FE54C25

Q35109118-5FB60571-7C27-4E0D-BAB3-20D8B04A854D

P2860

Q35109118-08C5E376-F996-47E1-99D2-73A3DEF7768F

Q35109118-0C1ED79D-FAAC-49C6-B15A-0DD5A3217C59

Q35109118-1083CF91-9739-46F5-B9F0-CB8EE4C4E497

Q35109118-11590BF1-0828-4018-A954-9F7D9B07FD70

Q35109118-11E928E9-6BC2-4013-8E0F-53C5C7F332A3

Q35109118-1275B52B-F769-42BB-A148-D3E6A5FDD985

Q35109118-28B4DE96-CF91-4894-AD28-4D6E4C4F068E

Q35109118-3181B829-C3DE-4397-B596-F46E22A09712

Q35109118-3E58A52C-9D6C-4431-BC7F-70EDC0604BEE

Q35109118-3FFB4414-E6FA-4B34-9B02-9347030D7194

P304

Q35109118-FE6A756E-A88C-4EAF-9945-4A78793EF04B

P31

Q35109118-7137D865-8BE8-4B65-9942-9A3039421FC9

P356

Q35109118-A7404AEE-F68B-40DF-9B74-FE9CA4618F39

P407

Q35109118-E235F231-5990-44E4-822D-2708DD032894

P433

Q35109118-C7691FBA-0902-4681-9802-258ED485F9DC

P478

Q35109118-7AFD7696-6B93-4499-87E6-D796E9CE191F

P50

Q35109118-D073FAE8-124B-4BEF-90F0-35BA8B7239D9

P577

Q35109118-F0AAF073-6EAC-47CC-AF87-1E6F30DA18F4

P698

Q35109118-3B99A6D6-1AFD-471B-B2D5-883BF00FD625

P932

Q35109118-1BD87BDF-3D93-419C-84EB-EACF227C955D

P356

P1433

The New England Journal of Medicine

P1476

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

@en

P2093

Anthony Turkiewicz

http://www.w3.org/2001/XMLSchema#string

Carol A Langford

http://www.w3.org/2001/XMLSchema#string

Coen Stegeman

http://www.w3.org/2001/XMLSchema#string

David Ikle

http://www.w3.org/2001/XMLSchema#string

David Weitzenkamp

http://www.w3.org/2001/XMLSchema#string

Duvuru Geetha

http://www.w3.org/2001/XMLSchema#string

E William St Clair

http://www.w3.org/2001/XMLSchema#string

Eugene Y Kissin

http://www.w3.org/2001/XMLSchema#string

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

Gary S Hoffman

http://www.w3.org/2001/XMLSchema#string

P2860

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Etanercept plus standard therapy for Wegener's granulomatosis.

Cyclophosphamide therapy in Wegener's granulomatosis.

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

The mechanisms of action of rituximab in the elimination of tumor cells.

Pathogenic roles of B cells in human autoimmunity; insights from the clinic.

Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies.

P304

221-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0909905

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Cees G M Kallenberg

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20647199

http://www.w3.org/2001/XMLSchema#string

P932

3137658

http://www.w3.org/2001/XMLSchema#string